Want to see VIR full AI Analyst Report?
VIR Stock Chart & Stats
$11.08
$0.21(2.47%)
At close: 4:00 PM EDT
$11.08
$0.21(2.47%)
Day’s Range― - ―
52-Week Range$4.75 - $11.94
Previous CloseN/A
Volume776.97K
Average Volume (3M)1.77M
Market Cap
$1.80B
Enterprise Value$1.28K
Total Cash (Recent Filing)$528.59M
Total Debt (Recent Filing)$93.27M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Oct 29, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding169,215,960
10 Day Avg. Volume2,005,469
30 Day Avg. Volume1,767,513
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.29Price Target Upside92.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$221.91M
Bulls Say, Bears Say
Bulls Say
Durable HDV Efficacy DifferentiationWeek-96 combination data show materially higher viral clearance than monotherapy, including a 35-point ITT advantage and 97% LOCF TND. If replicated in Phase III, this differentiation could support durable treatment adoption and a stronger position in HDV care.
Phase III Development ProgressCompleting enrollment in all three Phase III ECLIPSE studies reduces a major development uncertainty and establishes defined readouts through early 2027. The program is advancing toward regulatory and commercial preparation rather than remaining an early-stage concept.
Strong Liquidity And Cash RunwayThe projected runway into H2 2028 gives Vir time to fund late-stage trials and pipeline development without immediate financing pressure. This liquidity is especially valuable for a clinical-stage company whose programs require sustained investment before commercial revenue becomes recurring.
Bears Say
Persistent Cash ConsumptionNegative operating and free cash flow after 2022 means the company is consuming liquidity to fund operations rather than internally financing development. If this pattern persists, it can constrain portfolio choices and increase reliance on partnerships or future capital despite the current cash balance.
Dependence On Collaboration RevenueQ2 profitability was largely created by Astellas-related license revenue rather than recurring product sales. That makes reported earnings volatile and leaves near-term financial performance tied to milestone and upfront timing, while clinical programs still require substantial ongoing investment.
Limited HDV Diagnosis And Market UptakeHDV diagnosis is estimated at only 10–15% in the U.S., creating a structural limit on the addressable treated population today. Even with awareness and reflex testing, slower diagnosis expansion could delay uptake and reduce the pace at which clinical success converts into recurring product revenue.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.75 and its highest was $11.94 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.80B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Oct 29, 2026 which is in 44 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Aug 05, 2026. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.333 by $0.137.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.74.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 169,215,960 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of $0.47 in its last earnings report, beating expectations of $0.333. Following the earnings report the stock price went down -3.787%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.29 (92.11% Upside)
$21.29 (92.11% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 75%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 476.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
115.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong clinical and commercial progress (notably robust SOLSTICE Week 96 efficacy, completion of registrational enrollment for ECLIPSE, manufacturing milestones for drug substance, a strengthened balance sheet with ~ $1.01B cash and substantive Astellas funding, and accelerated oncology development with VIR-5500 expansion cohorts). Offsetting risks include higher R&D and SG&A driven by milestone and one-time items, reliance on collaboration revenue for near-term profitability, low current HDV diagnosis rates that could limit short-term market uptake, remaining CMC/drug product activities, and ongoing C-suite hiring. On balance, the positives (clinical data, enrollment completion, cash runway, strategic partnerships and oncology momentum) materially outweigh the near-term operational and market risks.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$21.29
▲(92.11% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
13.82% Mutual Funds
29.86% Other Institutional Investors
21.71% Public Companies and
Individual Investors